IntelliPharma Insights·Nov 8, 2025Red Breakthrough: The Battle of Chinese GLP-1 Challenging the GiantsOn August 7, 2025, Eli Lilly announced the Phase III clinical data of its oral weight loss drug Orforglipron, which showed that patients…
IntelliPharma Insights·Sep 21, 2025The GLP-1 Wars: How Novo Nordisk’s Fatal Missteps Paved the Way for Lilly’s Dual-Target…Being too far ahead of your time is indistinguishable from being wrong. ― Howard Marks, The Most Important Thing Illuminated…
IntelliPharma Insights·Sep 16, 2025From Fragmented to Flawless: How AI is Architecting Holistic Drug DevelopmentTime will tell if AIDD proves to be the better way to achieve HDD vision…
IntelliPharma Insights·Sep 14, 2025The Plasmid Bottleneck in Protein DesignIn late June, Chai Discovery published its Chai-2 model and related research findings on the bioRxiv. This model achieved breakthrough…
IntelliPharma Insights·Sep 7, 2025Palantir’s Blueprint for Escaping the Capital Trap in AI Drug DiscoveryThe first half of 2025 witnessed significant growth momentum in AI Agent applications, with the AI coding sector achieving substantial…
IntelliPharma Insights·Sep 6, 2025From Drug to Medicine: How AIDD is Reshaping the Ethical Landscape of Drug DiscoveryI recently had an intriguing conversation with a friend in investment banking about the distinction between the terms “drug” and…